Paper Details

  1. Home
  2. Paper Details

N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.

Author: El-AbbadiM, ManfrediM G, MukherjeeP, PlattF M, RanesM K, SeyfriedT N

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

N-butyldeoxynojirimycin (N B-DNJ) inhibits the glucosyltransferase catalysing the first step in GSL biosynthesis. N B-DNJ (200 microM) inhibited the proliferation of the EPEN and CT-2A cells by 50%, but did not reduce cell viability. N B-DNJ treatment reduced the growth and ganglioside content of subcutaneous and intracerebral EPEN and CT-2A tumours by at least 50% compared to the untreated controls. We conclude that N B-DNJ may inhibit tumour growth through an effect on ganglioside biosynthesis and may be useful as a new chemotherapy for brain tumours.
Paper Details　
Original Abstract of the Article :
Abnormalities in glycosphingolipid (GSL) biosynthesis have been implicated in the oncogenesis and malignancy of brain tumours. GSLs comprise the gangliosides and the neutral GSLs and are major components of the cell surface glycocalyx. N -butyldeoxynojirimycin (N B-DNJ) is an imino sugar that inhibi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363859/

データ提供：米国国立医学図書館（NLM）

N-Butyldeoxynojirimycin: A Potential Weapon in the Desert of Brain Tumors

The battle against [brain tumors] is a complex and challenging one. This research explores the potential of [N-butyldeoxynojirimycin (N-B-DNJ)] as a novel [chemotherapeutic agent] for treating brain tumors. The study investigates the effects of N-B-DNJ on the growth and ganglioside composition of experimental mouse brain tumors, revealing potential therapeutic benefits.

N-B-DNJ: A Potential Oasis in the Desert of Tumor Growth

The research suggests that N-B-DNJ may inhibit tumor growth and alter ganglioside biosynthesis, offering a potential new weapon in the fight against brain tumors. It's like finding a hidden oasis in the vast and unforgiving desert of cancer treatment, providing a source of hope and potential for healing.

Brain Tumors: A Journey Towards Effective Treatment

This research highlights the importance of exploring novel therapeutic approaches to address the challenges of brain tumors, offering a path towards more effective treatment options. It’s like a desert traveler seeking new routes and resources to overcome the obstacles of a harsh landscape. This research provides a glimmer of hope for those battling this devastating disease.

Dr.Camel's Conclusion

This research offers a promising avenue for the development of new therapies for brain tumors, highlighting the potential of N-B-DNJ as a novel therapeutic agent.

Date :
  1. Date Completed 2001-06-14
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

11308262

DOI: Digital Object Identifier

PMC2363859

Related Literature

Article Analysis
・Side Effects of miglustat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.